PMV Pharmaceuticals
PMVP
104 hedge funds and large institutions have $333M invested in PMV Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 10 closing their positions.
148% more call options, than puts
Call options by funds: $3.98M | Put options by funds: $1.6M
24% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 33
3% more capital invested
Capital invested by funds: $324M → $333M (+$9.02M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.14% less ownership
Funds ownership: 113.06% → 111.92% (-1.1%)
2% less funds holding
Funds holding: 106 → 104 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.33M |
| 2 |
Alkeon Capital Management
New York
|
+$5.96M |
| 3 |
TLP
Tri Locum Partners
New York
|
+$4.56M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
+$2.98M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$4.5M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$4.44M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.41M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.18M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.12M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $6.06K | – | – | – |
|
102
Osaic Holdings
Scottsdale,
Arizona
| $1.74K | +$358 | +52 | +23% |
|
103
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
NA
104
NewEdge Advisors
New Orleans,
Louisiana
| $190 | +$213 | +31 | New |
|
|
105
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$4.44M | -698,184 | Closed |
|
|
SFM
106
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.18M | -187,800 | Closed |
|
107
UBS AM
Chicago,
Illinois
| – | -$297K | -62,355 | Closed |
|
|
HF
108
HRT Financial
New York
| – | -$302K | -48,323 | Closed |
|
109
Man Group
London,
United Kingdom
| – | -$262K | -41,800 | Closed |
|
110
Prudential Financial
Newark,
New Jersey
| – | -$209K | -33,360 | Closed |
|
|
XT
111
XTX Topco
George Town,
Cayman Islands
| – | -$170K | -27,225 | Closed |
|
112
Squarepoint
New York
| – | -$119K | -19,041 | Closed |
|
113
Walleye Capital
New York
| – | -$71.8K | -11,471 | Closed |
|
114
Russell Investments Group
London,
United Kingdom
| – | -$9.96K | -1,592 | Closed |
|
PMVP Hedge Fund Activity: Q3 2023 in Review
104 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2023, worth a combined $333M — up 2.8% from $324M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of PMVP and 8 opened new positions — a net loss of 2 holders — while 33 trimmed existing stakes and 41 added.
The largest buyer was PFM Health Sciences, adding an estimated $7.33M. The largest seller was RTW Investments, cutting an estimated $4.5M.
- 104 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2023, down from 106 in Q2 2023.
- Funds reported $333M of PMV Pharmaceuticals stock for Q3 2023, up 2.8% quarter-over-quarter.
- 8 funds opened new PMV Pharmaceuticals positions in Q3 2023 and 10 closed out, a net change of -2 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2023 was PFM Health Sciences, an estimated $7.33M added.
- The largest PMV Pharmaceuticals seller in Q3 2023 was RTW Investments, an estimated $4.5M sold.
Based on aggregated 13F filings for Q3 2023.